These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 8842596)
1. Insulin underdelivery from implanted pumps using peritoneal route. Determinant role of insulin pump compatibility. Renard E; Bouteleau S; Jacques-Apostol D; Lauton D; Gibert-Boulet F; Costalat G; Bringer J; Jaffiol C Diabetes Care; 1996 Aug; 19(8):812-7. PubMed ID: 8842596 [TBL] [Abstract][Full Text] [Related]
2. Catheter complications associated with implantable systems for peritoneal insulin delivery. An analysis of frequency, predisposing factors, and obstructing materials. Renard E; Baldet P; Picot MC; Jacques-Apostol D; Lauton D; Costalat G; Bringer J; Jaffiol C Diabetes Care; 1995 Mar; 18(3):300-6. PubMed ID: 7555471 [TBL] [Abstract][Full Text] [Related]
3. Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experience. Gin H; Renard E; Melki V; Boivin S; Schaepelynck-Bélicar P; Guerci B; Selam JL; Brun JM; Riveline JP; Estour B; Catargi B; Diabetes Metab; 2003 Dec; 29(6):602-7. PubMed ID: 14707889 [TBL] [Abstract][Full Text] [Related]
4. Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabète du Traitement par Implants Actifs. Hanaire-Broutin H; Broussolle C; Jeandidier N; Renard E; Guerci B; Haardt MJ; Lassmann-Vague V Diabetes Care; 1995 Mar; 18(3):388-92. PubMed ID: 7555483 [TBL] [Abstract][Full Text] [Related]
5. Clinical trial of programmable implantable insulin pump for type I diabetes. Selam JL; Micossi P; Dunn FL; Nathan DM Diabetes Care; 1992 Jul; 15(7):877-85. PubMed ID: 1516508 [TBL] [Abstract][Full Text] [Related]
6. Implanted programmable insulin pumps: one hundred fifty-three patient years of surgical experience. Udelsman R; Chen H; Loman K; Pitt HA; Saudek CD Surgery; 1997 Dec; 122(6):1005-11. PubMed ID: 9426413 [TBL] [Abstract][Full Text] [Related]
7. Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump. Kessler L; Tritschler S; Bohbot A; Sigrist S; Karsten V; Boivin S; Dufour P; Belcourt A; Pinget M Diabetes Care; 2001 Feb; 24(2):302-7. PubMed ID: 11213883 [TBL] [Abstract][Full Text] [Related]
8. Catheter survival during long-term insulin therapy with an implanted programmable pump. The Implantable Insulin Pump Trial Study Group. Scavini M; Galli L; Reich S; Eaton RP; Charles MA; Dunn FL Diabetes Care; 1997 Apr; 20(4):610-3. PubMed ID: 9096988 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic procedures for catheter malfunction in programmable implantable intraperitoneal insulin infusion devices. Olsen CL; Turner DS; Iravani M; Waxman K; Selam JL; Charles MA Diabetes Care; 1995 Jan; 18(1):70-6. PubMed ID: 7698051 [TBL] [Abstract][Full Text] [Related]
10. Lower rate of initial failures and reduced occurrence of adverse events with a new catheter model for continuous subcutaneous insulin infusion: prospective, two-period, observational, multicenter study. Renard E; Guerci B; Leguerrier AM; Boizel R; Diabetes Technol Ther; 2010 Oct; 12(10):769-73. PubMed ID: 20809682 [TBL] [Abstract][Full Text] [Related]
11. Insulin pump-associated adverse events are common, but not associated with glycemic control, socio-economic status, or pump/infusion set type. Ross P; Gray AR; Milburn J; Kumarasamy IM; Wu F; Farrand S; Armishaw J; Wiltshire E; Rayns J; Tomlinson P; Wheeler BJ Acta Diabetol; 2016 Dec; 53(6):991-998. PubMed ID: 27585938 [TBL] [Abstract][Full Text] [Related]
12. Implantable insulin pumps. A position statement about their clinical use. Renard E; Schaepelynck-Bélicar P; Diabetes Metab; 2007 Apr; 33(2):158-66. PubMed ID: 17300973 [TBL] [Abstract][Full Text] [Related]
13. A preliminary trial of the programmable implantable medication system for insulin delivery. Saudek CD; Selam JL; Pitt HA; Waxman K; Rubio M; Jeandidier N; Turner D; Fischell RE; Charles MA N Engl J Med; 1989 Aug; 321(9):574-9. PubMed ID: 2761602 [TBL] [Abstract][Full Text] [Related]
14. Sudden death due to diabetic ketoacidosis following power failure of an insulin pump: Autopsy and pump data. Kjærulff MLBG; Astrup BS J Forensic Leg Med; 2019 Apr; 63():34-39. PubMed ID: 30856551 [TBL] [Abstract][Full Text] [Related]
15. Reduced Silent Occlusions with a Novel Catheter Infusion Set (BD FlowSmart): Results from Two Open-Label Comparative Studies. Gibney M; Xue Z; Swinney M; Bialonczyk D; Hirsch L Diabetes Technol Ther; 2016 Mar; 18(3):136-43. PubMed ID: 26701357 [TBL] [Abstract][Full Text] [Related]
20. Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Heinemann L; Fleming GA; Petrie JR; Holl RW; Bergenstal RM; Peters AL Diabetes Care; 2015 Apr; 38(4):716-22. PubMed ID: 25776138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]